Roivant reported a Phase 2b failure for IMVT-1402 (imeroprubart) in a form of lupus, stating the program did not improve symptoms. The result adds another cautionary datapoint for FcRn biology in clinical translation. While the company’s broader autoimmune strategy remains under question given multiple discontinued or underperforming assets across the class, the Phase 2b outcome is likely to influence future trial design, comparator selection, and endpoint choices in lupus programs. For investors, the failure affects expectations for timelines and potential licensing leverage tied to symptom-driven primary endpoints. The move also sets up renewed scrutiny of how autoimmune lupus subtypes respond to targeted immunomodulation and whether patient selection will become the differentiating factor in next-generation trials.